Furthermore, AML is highly heterogeneous and has different clinical classifications and driver gene (including FLT3, CEBPA, U2AF1 and EZH2) abnormalities [26–28], which means different types of AML exhibit different responses to the same drug. This evidence concerns the gene FLT3 and acute myeloid leukemia.